Microbot Medical Expands LIBERTY Robotic System Adoption with First North Carolina Customer
MBOT sits 22% above its 52-week low of $1.6.
Summary
Microbot Medical announced it has secured its first North Carolina-based customer, a leading academic center, for its LIBERTY Endovascular Robotic System, expanding its geographic footprint.
Key Events · Product Development and Regulatory · MBOT
-
First North Carolina Customer Secured
Microbot Medical announced it has secured its first North Carolina-based customer, a leading academic center, for its LIBERTY Endovascular Robotic System.
-
Broadening Geographic Penetration
This new adoption expands the LIBERTY system's geographic footprint, demonstrating penetration from the southeast, mid-Atlantic, and northeast U.S.
-
Continued Commercial Momentum
This follows recent positive commercial developments, including the full market release, strong Q2 revenue generation, and Israeli regulatory approval for the LIBERTY system.
Analysis · MBOT · Industrial Applications And Services
This filing highlights Microbot Medical's continued progress in commercializing its LIBERTY Endovascular Robotic System by securing a new customer in a key region. While specific financial terms of the deal are not disclosed, adding a "leading Academic Center" in North Carolina expands the system's footprint and validates its market acceptance. This news reinforces the positive commercial momentum the company has been building, as evidenced by recent successful market releases and regulatory approvals.
At the time of this filing, MBOT was trading at $1.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $133M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.